Cencora, Inc.

Cencora Q3 FY26 — Strong Specialty Performance Drives Double-Digit Operating Income and Raised EPS Guidance

Cencora Q2 FY26 — EPS +7.5%, EPS/OI guidance raised, buybacks resume amid transitory revenue headwinds

Cencora Q1 FY26 — Strong Specialty Performance and OneOncology Acquisition Drive Raised Guidance

Cencora Q4 FY25 — Strong Specialty Performance Drives Raised Long-Term Guidance

Cencora Q3 FY25 — Strong U.S. Performance Drives Raised FY25 Guidance

Cencora Q2 FY25 — Strong U.S. Performance Drives Raised Full-Year Guidance

Cencora Q1 FY25 — Strong U.S. Performance Drives Raised EPS Guidance